Our September meeting continued virtual by member preference.
Beacon members entertained a new funding proposal from Vincere Biosciences, which is developing small molecule therapeutics targeting mitochondrial quality control to cure age-related and neurodegenerative diseases.
Members reported on companies in due diligence consisting of:
- Ocular Technologies, and
- RevMedica.
We heard updates on new or renewed funding rounds for:
- Diesel Labs,
- First Light Diagnostics,
- Theromics, and
- GelMEDIX.
